JP2017500320A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017500320A5 JP2017500320A5 JP2016540552A JP2016540552A JP2017500320A5 JP 2017500320 A5 JP2017500320 A5 JP 2017500320A5 JP 2016540552 A JP2016540552 A JP 2016540552A JP 2016540552 A JP2016540552 A JP 2016540552A JP 2017500320 A5 JP2017500320 A5 JP 2017500320A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- inhibitor
- cas number
- delta
- intellikine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361919625P | 2013-12-20 | 2013-12-20 | |
| US61/919,625 | 2013-12-20 | ||
| PCT/US2014/071724 WO2015095825A1 (en) | 2013-12-20 | 2014-12-19 | Cancer treatments using combinations of type 2 mek and erk inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017500320A JP2017500320A (ja) | 2017-01-05 |
| JP2017500320A5 true JP2017500320A5 (enExample) | 2018-02-08 |
| JP6678583B2 JP6678583B2 (ja) | 2020-04-22 |
Family
ID=53403790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016540552A Active JP6678583B2 (ja) | 2013-12-20 | 2014-12-19 | ２型ｍｅｋ阻害剤およびｅｒｋ阻害剤の組み合わせを用いるがん処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11007184B2 (enExample) |
| EP (3) | EP4389225A3 (enExample) |
| JP (1) | JP6678583B2 (enExample) |
| AU (1) | AU2014368912B2 (enExample) |
| ES (2) | ES2953311T3 (enExample) |
| WO (1) | WO2015095825A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG187426A1 (en) | 2008-01-04 | 2013-02-28 | Intellikine Llc | Certain chemical entities, compositions and methods |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| EP3238722B1 (en) | 2011-01-10 | 2019-03-13 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| EP2914296B2 (en) | 2012-11-01 | 2021-09-29 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| US11147818B2 (en) | 2016-06-24 | 2021-10-19 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| EP4023769A1 (en) * | 2016-08-31 | 2022-07-06 | The Children's Hospital of Philadelphia | Compositions and methods for the diagnosis and treatment of lymphatic system disorders |
| JP7341060B2 (ja) * | 2017-02-10 | 2023-09-08 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Ｍａｐｋ経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物 |
| JP7405408B2 (ja) * | 2017-05-16 | 2023-12-26 | バイオメッド バレー ディスカバリーズ，インコーポレイティド | 異型ｂｒａｆ変異を有するがんを処置するための組成物および方法 |
| US11406605B2 (en) * | 2017-12-20 | 2022-08-09 | Golden Biotechnology Corporation | Therapeutic compositions for treating pancreatic cancer |
| US11395823B2 (en) | 2018-01-09 | 2022-07-26 | Duke University | Topical administration of MEK inhibiting agents for the treatment of skin disorders |
| PH12022551661A1 (en) | 2020-01-10 | 2023-11-29 | Immuneering Corp | Mek inhibitors and therapeutic uses thereof |
| US11084780B1 (en) | 2021-02-17 | 2021-08-10 | Springworks Therapeutics, Inc. | Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
| US11066358B1 (en) | 2021-02-17 | 2021-07-20 | Warner-Lambert Company Llc | Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| JPH08507926A (ja) | 1993-03-19 | 1996-08-27 | シーケノム・インコーポレーテツド | エキソヌクレアーゼ分解を介した質量分析法によるｄｎａ配列決定 |
| US6140053A (en) | 1996-11-06 | 2000-10-31 | Sequenom, Inc. | DNA sequencing by mass spectrometry via exonuclease degradation |
| US7601497B2 (en) | 2000-06-15 | 2009-10-13 | Qiagen Gaithersburg, Inc. | Detection of nucleic acids by target-specific hybrid capture method |
| US7439016B1 (en) | 2000-06-15 | 2008-10-21 | Digene Corporation | Detection of nucleic acids by type-specific hybrid capture method |
| GB0320059D0 (en) | 2003-08-27 | 2003-10-01 | Solexa Ltd | A method of sequencing |
| HUE047130T2 (hu) | 2004-05-14 | 2020-04-28 | Vertex Pharma | Pirrol-származékok mint az erk-fehérjekinázok inhibitorai és ilyen vegyületeket tartalmazó gyógyászati készítmények |
| US7582623B2 (en) | 2004-05-20 | 2009-09-01 | The Regents Of The University Of California | Photoactive metal nitrosyls for blood pressure regulation and cancer therapy |
| US20060228721A1 (en) | 2005-04-12 | 2006-10-12 | Leamon John H | Methods for determining sequence variants using ultra-deep sequencing |
| TW200829234A (en) * | 2007-01-08 | 2008-07-16 | Golden Biotechnology Corp | Antrodia camphorata isophorone extract |
| TW200911262A (en) * | 2007-06-05 | 2009-03-16 | Schering Corp | Novel compounds that are ERK inhibitors |
| TWI419974B (zh) | 2008-10-27 | 2013-12-21 | Qiagen Gaithersburg Inc | 於自動平台上之快速結果雜交捕捉法 |
| KR20120046018A (ko) | 2010-10-04 | 2012-05-09 | 삼성테크윈 주식회사 | 단일 뉴클레오티드 다형성의 실시간 ｐｃｒ 검출 |
| US20130217721A1 (en) * | 2010-11-19 | 2013-08-22 | The Regents Of The University Of California | Compositions and methods for detection and treatment of b-raf inhibitor-resistant melanomas |
| US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
| US20130023531A1 (en) | 2011-01-27 | 2013-01-24 | Boehringer Ingelheim International Gmbh | Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors |
| WO2012125848A2 (en) | 2011-03-16 | 2012-09-20 | Baylor College Of Medicine | A method for comprehensive sequence analysis using deep sequencing technology |
| WO2013187983A1 (en) | 2012-06-15 | 2013-12-19 | The Wistar Institute Of Anatomy And Biology | Methods an compositions for treating or diagnosing melanoma |
-
2014
- 2014-12-19 WO PCT/US2014/071724 patent/WO2015095825A1/en not_active Ceased
- 2014-12-19 EP EP24164571.2A patent/EP4389225A3/en active Pending
- 2014-12-19 EP EP21193832.9A patent/EP3984537B1/en active Active
- 2014-12-19 EP EP14871217.7A patent/EP3082779B1/en active Active
- 2014-12-19 ES ES14871217T patent/ES2953311T3/es active Active
- 2014-12-19 JP JP2016540552A patent/JP6678583B2/ja active Active
- 2014-12-19 AU AU2014368912A patent/AU2014368912B2/en active Active
- 2014-12-19 ES ES21193832T patent/ES2986019T3/es active Active
- 2014-12-19 US US15/105,871 patent/US11007184B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017500320A5 (enExample) | ||
| JP2017502017A5 (enExample) | ||
| JP2017502013A5 (enExample) | ||
| JP2017502016A5 (enExample) | ||
| Leonard et al. | AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma | |
| Tahara et al. | Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02) | |
| RU2016129287A (ru) | Лечение злокачественных опухолей с применением комбинаций ингибиторов erk и raf | |
| Zarogoulidis et al. | mTOR pathway: A current, up-to-date mini-review | |
| JP7405408B2 (ja) | 異型ｂｒａｆ変異を有するがんを処置するための組成物および方法 | |
| Fazio et al. | A phase II study of BEZ235 in patients with everolimus-resistant, advanced pancreatic neuroendocrine tumours | |
| Beuselinck et al. | Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases | |
| Budde et al. | Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed/refractory (R/R) follicular lymphoma (FL) who have received≥ 2 prior lines of therapy: pivotal results from a phase I/II study | |
| O’Sullivan | Overcoming endocrine resistance in hormone-receptor positive advanced breast cancer-the emerging role of CDK4/6 inhibitors | |
| JP2020519660A5 (enExample) | ||
| JP2017502014A5 (enExample) | ||
| Oudard et al. | Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma—Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study | |
| KR20140036193A (ko) | 아플리버셉트, 폴린산, 5-플루오로우라실(5-fu) 및 이리노세탄(folfiri)을 포함하는 조성물 | |
| CA2939464A1 (en) | Use of anti-ccr5 antibodies in graft versus host disease | |
| MX2014002471A (es) | Combinaciones sinergicas de los inhibidores de p13k y mek. | |
| Yoon et al. | Intracranial regression of an advanced basal cell carcinoma using sonidegib and itraconazole after failure with vismodegib | |
| Bracarda et al. | Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY) | |
| JP2018519324A5 (enExample) | ||
| Besse et al. | A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer | |
| Dummer et al. | Integrating first-line treatment options into clinical practice: what’s new in advanced melanoma? | |
| Lin et al. | Severe neuropathic pain with concomitant administration of vincristine and posaconazole |